liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A cost-effectiveness study comparing the as-needed use of formoterol (Oxis®) and terbutaline (Bricanyl®) in patients with moderate to severe asthma
AstraZeneca RandD Lund, Lund, Lund University Centre for Health Economics (LUCHE), Lund.
2001 (English)In: Respiratory Medicine, ISSN 0954-6111, E-ISSN 1532-3064, Vol. 95, no 9, 753-758 p.Article in journal (Refereed) Published
Abstract [en]

This study evaluated the economic and health-related consequences of the as-needed use of a long-acting ß2-agonist with fast onset (formoterol,Oxis® Turbuhaler® 4.5 µg) versus a short-acting ß2-agonist (terbutaline, Bricanyl® Turbuhaler® 0.5 mg) in patients with moderate to severe asthma. A multi-national (Sweden, Norway, The Netherlands and Greece), multi-centre (35 centres), randomized, double-blind clinical trial was conducted using 362 patients on inhaled steroids during a 12-week period. The effectiveness results were pooled and the total costs included estimates for ß2-agonists, inhaled steroids, oral steroids, physician visits and sick-leave. The 182 patients in the formoterol group had 14404 days of exposure and 29 severe exacerbations, and the 180 patients in the terbutaline group had 13655 days of exposure and 48 severe exacerbations. The terbutaline group had 62% more severe exacerbations than the formoterol group (P=0.039), based on exposure time. Per patient, the calculated total costs were SEK 3386 for the formoterol group and SEK 3709 for the terbutaline group over the 12-week period. The conclusion is that the use of Oxis® Turbuhaler® instead of Bricanyl® Turbuhaler® for as-needed treatment is a more effective treatment generating cost savings from a societal perspective. © 2001 Harcourt Publishers Ltd.

Place, publisher, year, edition, pages
2001. Vol. 95, no 9, 753-758 p.
Keyword [en]
ß2-agonist, Asthma, Cost-effectiveness, Formoterol, Severe exacerbations, Terbutaline
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:liu:diva-47243DOI: 10.1053/rmed.2001.1131OAI: oai:DiVA.org:liu-47243DiVA: diva2:268139
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-13

Open Access in DiVA

No full text

Other links

Publisher's full text
In the same journal
Respiratory Medicine
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 57 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf